S3-Guideline "diagnosis, therapy and follow-up of melanoma" - Short version;S3-Leitlinie "diagnostik, Therapie und Nachsorge des Melanoms" - Kurzfassung

JDDG - Journal of the German Society of Dermatology

Volumn 11, Issue 6, 2013, Pages 563-602

  Pflugfelder, Annette ^a   Kochs, Corinna ^b   Blum, Andreas ^c   Capellaro, Marcus ^d   Czeschik, Christina ^b   Dettenborn, Therese ^e   Dill, Dorothee ^f   Dippel, Edgar ^g   Eigentler, Thomas ^a   Feyer, Petra ^h   Follmann, Markus ⁱ   Frerich, Bernhard ^j   Ganten, Maria Katharina ^k   Gärtner, Jan ^l   Gutzmer, Ralf ^m   Hassel, Jessica ^k   Hauschild, Axel ⁿ   Hohenberger, Peter ^o   Hübner, Jutta ^p   Kaatz, Martin ^q   Kleeberg, Ulrich R ^r   Kölbl, Oliver ^s   Kortmann, Rolf Dieter ^t   Krause Bergmann, Albrecht ^e   Kurschat, Peter ^l   Leiter, Ulrike ^a   Link, Hartmut ^u   Loquai, Carmen ^v   Löser, Christoph ^g   MacKensen, Andreas ^w   Meier, Friedegund ^a   Mohr, Peter ^d   Möhrle, Matthias ^a,x   Nashan, Dorothee ^y   Reske, Sven ^z   Rose, Christian ^aa   Sander, Christian ^ab   Satzger, Imke ^m   Schiller, Meinhard ^ac   Schlemmer, Heinz Peter ^k   Strittmatter, Gerhard ^e   Sunderkötter, Cord ^ac   Swoboda, Lothar ^ad   Trefzer, Uwe ^ae   Voltz, Raymond ^l   Vordermark, Dirk ^af   Weichenthal, Michael ⁿ   Werner, Andreas ^ag   Wesselmann, Simone ⁱ   Weyergraf, Ansgar J ^ah   Wick, Wolfgang ^ai   Garbe, Claus ^a   Schadendorf, Dirk ^b   more..

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Private and Teaching Practice of Dermatology   (Germany)

^d Association of Dermatological Prevention   (Germany)

^e Fachklinik Hornheide   (Germany)

^f Hautklinik Lüdenscheidt   (Germany)

^g KLINIKUM LUDWIGSHAFEN   (Germany)

^h Nuclear Medicine   (Germany)

ⁱ German Cancer Society Berlin   (Germany)

^j UNIVERSITY OF ROSTOCK   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^m HANNOVER MEDICAL SCHOOL   (Germany)

ⁿ UNIVERSITY OF KIEL   (Germany)

^o Mannheim University Medical Center   (Germany)

^p GOETHE UNIVERSITY   (Germany)

^q SRH Waldklinikum Gera Gmbh   (Germany)

^r Hämatologisch Onkologische Praxis Altona HOPA   (Germany)

^s UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^t UNIVERSITY OF LEIPZIG   (Germany)

^u Westpfalz Klinikum GmbH   (Germany)

^v JOHANNES GUTENBERG UNIVERSITY   (Germany)

^w UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^x Praxisklinik Tübingen Haut und Venen   (Germany)

^y KLINIKUM DORTMUND   (Germany)

^z UNIVERSITY HOSPITAL ULM   (Germany)

^aa Klinikum Dortmund GGmbH ^*

^ab DEPARTMENT OF CARDIOLOGY   (Germany)

^ac UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^ad German Society of Surgery   (Germany)

^ae CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^af MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^ag Tumor Center Rhineland Palatinate   (Germany)

^ah Bad Bentheim Hospital   (Germany)

^ai UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DETORUBICIN; FOTEMUSTINE; GEMCITABINE; HYDROXYUREA; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; LACTATE DEHYDROGENASE; LEVAMISOLE; LOMUSTINE; MELPHALAN; PACLITAXEL; PEGINTERFERON; PROTEIN S100B; TEMOZOLOMIDE; TREOSULFAN; TUMOR MARKER; VINCRISTINE; VINDESINE;

ABDOMINAL RADIOGRAPHY; ANEMIA; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRYOSURGERY; DIGITAL IMAGING; DISTANT METASTASIS; DOCTOR PATIENT RELATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ECHOGRAPHY; ELECTIVE SURGERY; ELECTROCHEMOTHERAPY; EPILUMINESCENCE MICROSCOPY; EXCISION; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC LIMB PERFUSION; HYPERTHERMIC THERAPY; LASER SURGERY; LEUKOPENIA; LIVER METASTASIS; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MEDICAL LITERATURE; MELANOMA; MICROMETASTASIS; MOLECULAR PATHOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SAFETY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RADIATION DOSE; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REGIONAL METASTASIS; REHABILITATION CARE; RELATIVE; SELF EXAMINATION; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SEQUENTIAL DIGITAL DERMATOSCOPY; SYSTEMATIC REVIEW (TOPIC); THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT INDICATION; TUMOR VOLUME; VISCUM ALBUM; WHOLE BODY CT; WHOLE BODY MRI; WHOLE BODY PET; DERMATOLOGY; GERMANY; ONCOLOGY; SKIN NEOPLASMS; STANDARDS; CANCER PATIENT; EVIDENCE BASED MEDICINE; REVIEW;

DERMATOLOGY; FOLLOW-UP STUDIES; GERMANY; HUMANS; MEDICAL ONCOLOGY; MELANOMA; SKIN NEOPLASMS;

EID: 84891898067     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12044     Document Type: Article

References (262)

1. Robert Koch-Institut. http://www.rki.de 2012.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Jr., Morton DL, Ross MI, Sober AJ, Sondak VK,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
3. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, Colman MH, Zhang Y,. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-98.
4. The Cancer Council Australia and Australian Cancer Network SaNZGGW. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. 2008.
5. Martin RC, Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Edwards MJ, McMasters KM,. Is incisional biopsy of melanoma harmful? Am J Surg 2005; 190: 913-7.
6. Pflugfelder A, Weide B, Eigentler TK, Forschner A, Leiter U, Held L, Meier F, Garbe C,. Incisional biopsy and melanoma prognosis: Facts and controversies. Clin Dermatol 2010; 28: 316-8.
7. Ng JC, Swain S, Dowling JP, Wolfe R, Simpson P, Kelly JW,. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch.Dermatol 2010; 146: 234-9.
8. Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, Hollis S, Lens MB, Thompson JF,. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009; 4: CD004835.
9. Kenady DE, Brown BW, McBride CM,. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. Surgery 1982; 92: 615-8.
10. McLeod M, Choudhary S, Giannakakis G, Nouri K,. Surgical Treatments for Lentigo Maligna: A Review Dermatol Surg 2011; 10-4725.
11. Stevenson O, Ahmed I,. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol 2005; 6: 151-64.
12. Mohrle M., [Micrographic controlled surgery (3D-histology) in cutaneous melanoma]. J Dtsch Dermatol Ges 2003; 1: 869-75.
13. Loser C, Rompel R, Breuninger H, Mohrle M, Hafner HM, Kunte C, Hassel J, Hohenleutner U, Podda M, Sebastian G, Hafner J, Konz B, Kaufmann R,. Microscopically controlled surgery (MCS). J Dtsch Dermatol Ges 2010; 8: 920-5.
14. Lichte V, Breuninger H, Metzler G, Haefner HM, Moehrle M,. Acral lentiginous melanoma: conventional histology vs. three-dimensional histology. Br J Dermatol 2009; 160: 591-9.
15. Moehrle M, Metzger S, Schippert W, Garbe C, Rassner G, Breuninger H,. ìFunctionalî surgery in subungual melanoma. Dermatol Surg 2003; 29: 366-74.
16. Moehrle M, Dietz K, Garbe C, Breuninger H,. Conventional histology vs. three-dimensional histology in lentigo maligna melanoma. The British journal of dermatology 2006; 154: 453-9.
17. Farshad A, Burg G, Panizzon R, Dummer R,. A retrospective study of 150 patients with lentigo maligna and lentigo ≠maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146: 1042-6.
18. Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, Plewig G, Volkenandt M,. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. Journal of the American Academy of Dermatology 2000; 43: 477-82.
19. Harwood AR,. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. International journal of radiation oncology, biology, physics 1983; 9: 1019-21.
20. Stevens G, Thompson JF, Firth I, OíBrien CJ, McCarthy WH, Quinn MJ,. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88: 88-94.
21. Storper IS, Lee SP, Abemayor E, Juillard G,. The role of radiation therapy in the treatment of head and neck cutaneous melanoma. Am J Otolaryngol 1993; 14: 426-31.
22. Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, Goepfert H, Ha CS, Byers RM,. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. International journal of radiation oncology, biology, physics 1994; 30: 795-8.
23. Foote MC, Burmeister B, Burmeister E, Bayley G, Smithers BM,. Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg 2008; 78: 273-6.
24. Vongtama R, Safa A, Gallardo D, Calcaterra T, Juillard G,. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck 2003; 25: 423-8.
25. Wasif N, Gray RJ, Pockaj BA,. Desmoplastic melanoma-the step-child in the melanoma family? J Surg Oncol 2011; 103: 158-62.
26. Sawyer A, McGoldrick RB, Mackey SP, Allan R, Powell B,. Does staging computered tomography change management in thick malignant melanoma? J Plast Reconstr Aesthet Surg 2009; 62: 453-6.
27. Yancovitz M, Finelt N, Warycha MA, Christos PJ, Mazumdar M, Shapiro RL, Pavlick AC, Osman I, Polsky D, Berman RS,. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007; 110: 1107-14.
28. Vereecken P, Laporte M, Petein M, Steels E, Heenen M,. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol 2005; 19: 66-73.
29. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN,. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011; 103: 129-42.
30. Schlamann M, Loquai C, Goericke S, Forsting M, Wanke I,. Cerebral MRI in neurological asymptomatic patients with ≠malignant melanoma. Rofo 2008; 180: 143-7.
31. Fogarty GB, Tartaglia C,. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. Clin Oncol (R.Coll.Radiol) 2006; 18: 360-2.
32. Wang TS, Johnson TM, Cascade PN, Redman BG, Sondak VK, Schwartz JL,. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004; 51: 399-405.
33. Hafner J, Schmid MH, Kempf W, Burg G, Kunzi W, Meuli-Simmen C, Neff P, Meyer V, Mihic D, Garzoli E, Jungius KP, Seifert B, Dummer R, Steinert H,. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004; 150: 677-86.
34. Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D,. Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 2002; 87: 151-7.
35. Terhune MH, Swanson N, Johnson TM,. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998; 134: 569-72.
36. Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W,. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004; 140: 67-70.
37. Bafounta ML, Beauchet A, Chagnon S, Saiag P,. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol 2004; 5: 673-80.
38. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G,. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21: 520-9.
39. Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M, Sertoli MR, Rosso R,. Stage I-II melanoma: the value of metastatic work-up. Oncology 1987; 44: 87-9.
40. Goerz G, Schulte-Beerbuhl R, Roder K, Schoppe WD, Munchhoff C, Jungblut RM,. Malignant melanoma: which examinations are useful in staging and follow-up? Dtsch Med Wochenschr 1986; 111: 1230-3.
41. Mocellin S, Zavagno G, Nitti D,. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008; 123: 2370-6.
42. Hofmann MA, Gussmann F, Fritsche A, Biesold S, Schicke B, Kuchler I, Voit C, Trefzer U,. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res 2009; 19: 17-23.
43. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B,. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003; 97: 1737-45.
44. Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU,. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001; 21: 1311-6.
45. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R,. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149-53.
46. Veit-Haibach P, Vogt FM, Jablonka R, Kuehl H, Bockisch A, Beyer T, Dahmen G, Rosenbaum S, Antoch G,. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging 2009; 36: 910-8.
47. Khansur T, Sanders J, Das SK,. Evaluation of staging workup in malignant melanoma. Arch Surg 1989; 124: 847-9.
48. Zartman GM, Thomas MR, Robinson WA,. Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol 1987; 35: 163-4.
49. Kersey PA, Iscoe NA, Gapski JA, Osoba D, From L, DeBoer G, Quirt IC,. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg 1985; 72: 614-7.
50. Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH,. Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Melanoma: A Meta-Analysis. J Clin Oncol 2011.
51. Warycha MA, Zakrzewski J, Ni Q, Shapiro RL, Berman RS, Pavlick AC, Polsky D, Mazumdar M, Osman I,. Meta-analysis of sentinel lymph node positivity in thin melanoma (
52. Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, Flaig M, Ruzicka T, Berking C, Schmid-Wendtner MH,. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res 2010; 20: 330-7.
53. Mays MP, Martin RC, Burton A, Ginter B, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Stromberg AJ, McMasters KM, Scoggins CR,. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer 2010; 116: 1535-44.
54. Testori A, De Salvo GL, Montesco MC, Trifiro G, Mocellin S, Landi G, Macripo G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Soteldo J, Casara D, Schiavon M, Vecchiato A, Pasquali S, Baldini F, Mazzarol G, Rossi CR, Italian M, I. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol 2009; 16: 2018-27.
55. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ, MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-17.
56. McMasters KM, Wong SL, Edwards MJ, Ross MI, Chao C, Noyes RD, Viar V, Cerrito PB, Reintgen DS,. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001; 130: 151-6.
57. Puleo CA, Messina JL, Riker AI, Glass LF, Nelson C, Cruse CW, Johnson TM, Sondak VK,. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005; 12: 230-5.
58. Socrier Y, Lauwers-Cances V, Lamant L, Garrido I, Lauwers F, Lopez R, Rochaix P, Chevreau C, Payoux P, Viraben R, Paul C, Meyer N,. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. Br J Dermatol 2010; 162: 830-4.
59. Kaur MR, Colloby PS, Martin-Clavijo A, Marsden JR,. Melanoma histopathology reporting: are we complying with the National Minimum Dataset? J Clin Pathol 2007; 60: 1121-3.
60. Even-Sapir E, Lerman H, Lievshitz G, Khafif A, Fliss DM, Schwartz A, Gur E, Skornick Y, Schneebaum S,. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med 2003; 44: 1413-20.
61. Mar MV, Miller SA, Kim EE, Macapinlac HA,. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. J Nucl Med Technol 2007; 35: 10-6.
62. Dengel LT, More MJ, Judy PG, Petroni GR, Smolkin ME, Rehm PK, Majewski S, Williams MB, Slingluff CL, Jr., Intraoperative imaging guidance for sentinel node biopsy in melanoma ≠using a mobile gamma camera. Ann Surg 2010.
63. Vidal-Sicart S, Paredes P, Zanon G, Pahisa J, Martinez-Roman S, Caparros X, Vilalta A, Rull R, Pons F,. Added value of intraoperative real-time imaging in searches for difficult-to-locate sentinel nodes. J Nucl Med 2010; 51: 1219-25.
64. Wendler T, Herrmann K, Schnelzer A, Lasser T, Traub J, Kutter O, Ehlerding A, Scheidhauer K, Schuster T, Kiechle M, Schwaiger M, Navab N, Ziegler SI, Buck AK,. First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. Eur J Nucl Med Mol Imaging 2010; 37: 1452-61.
65. Kretschmer L, Peeters S, Beckmann I, Thoms KM, Mitteldorf C, Emmert S, Sahlmann CO, Bertsch HP, Neumann C, Meller J,. Intraoperative detection of sentinel lymph nodes in cutaneous malignant melanoma-blue dye alone versus blue dye plus gamma detection. J Dtsch Dermatol Ges 2005; 3: 615-22.
66. Bostick P, Essner R, Glass E, Kelley M, Sarantou T, Foshag LJ, Qi K, Morton D,. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999; 134: 43-9.
67. King TA, Fey JV, Van Zee KJ, Heerdt AS, Gemignani ML, Port ER, Sclafani L, Sacchini V, Petrek JA, Cody HS, III, Borgen PI, Montgomery LL,. A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer. Ann Surg Oncol 2004; 11: 535-41.
68. Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, Kissin MW, Powell BW, EORTC Melanoma Group. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200: 314-9.
69. Gietema HA, Vuylsteke RJ, de Jonge IA, van Leeuwen PA, Molenkamp BG, van der Sijp JR, Meijer S, van Diest PJ,. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 2004; 57: 618-20.
70. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T,. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 2004; 100: 1683-91.
71. Spanknebel K, Coit DG, Bieligk SC, Gonen M, Rosai J, Klimstra DS,. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005; 29: 305-17.
72. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, Pijpers R, Morton DL,. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 89: 236-41.
73. Van, Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, Kliffen M,. Clinical relevance of melanoma ≠micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17: 1578-85.
74. Meier A, Satzger I, Volker B, Kapp A, Gutzmer R,. Comparison of classification systems in melanoma sentinel lymph nodes-an analysis of 697 patients from a single center. Cancer 2010; 116: 3178-88.
75. Murali R, Desilva C, Thompson JF, Scolyer RA,. Non-sentinel node risk score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol 2010.
76. Satzger I, Volker B, Meier A, Kapp A, Gutzmer R,. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol 2008; 15: 1723-32.
77. Starz H, Balda BR, Kramer KU, Buchels H, Wang H,. A micromorphometry- based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001; 91: 2110-21.
78. Starz H, Siedlecki K, Balda BR,. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004; 11: 162S-8S.
79. Satzger I, Volker B, Al Ghazal M, Meier A, Kapp A, Gutzmer R,. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology 2007; 50: 764-72.
80. Scolyer RA, Li LX, McCarthy SW, Shaw HM, Stretch JR, Sharma R, Thompson JF,. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 2004; 122: 532-9.
81. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Jr., Morton DL, Ross MI, Sondak VK,. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28: 2452-9.
82. van der Ploeg IM, Kroon BB, Antonini N, Valdes Olmos RA, Nieweg OE,. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? Ann Surg 2009; 249: 1003-7.
83. Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ,. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 2009; 16: 3455-62.
84. Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W,. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Br J Dermatol 2008; 159: 597-605.
85. Tas F, Yasasever V, Duranyildiz D, Camlica H, Ustuner Z, Aydiner A, Topuz E,. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma. Am J Clin Oncol 2004; 27: 225-8.
86. van der Ploeg AP, Van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM,. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria. J Clin Oncol 2011.
87. Creagan ET, Cupps RE, Ivins JC, Pritchard DJ, Sim FH, Soule EH, OíFallon JR,. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 1978; 42: 2206-10.
88. Bibault JE, Dewas S, Mirabel X, Mortier L, Penel N, Vanseymortier L, Lartigau E,. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 2011; 6: 12.
89. Gojkovic-Horvat A, Jancar B, Blas M, Zumer B, Karner K, Hocevar M, Strojan P,. Adjuvant radiotherapy for palpable melanoma metastases to the groin: when to irradiate? International journal of radiation oncology, biology, physics 2011.
90. Strojan P, Jancar B, Cemazar M, Perme MP, Hocevar M,. Melanoma metastases to the neck nodes: role of adjuvant irradiation. International journal of radiation oncology, biology, physics 2010; 77: 1039-45.
91. Agrawal S, Kane JM, III, Guadagnolo BA, Kraybill WG, Ballo MT,. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115: 5836-44.
92. Hamming-Vrieze O, Balm AJ, Heemsbergen WD, Hooft van Huysduynen T, Rasch CR,. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. Arch Otolaryngol Head Neck Surg 2009; 135: 795-800.
93. Moncrieff MD, Martin R, OíBrien CJ, Shannon KF, Clark JR, Gao K, McCarthy WM, Thompson JF,. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol 2008; 15: 3022-7.
94. Shen P, Wanek LA, Morton DL,. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol 2000; 7: 554-9.
95. OíBrien CJ, Petersen-Schaefer K, Stevens GN, Bass PC, Tew P, Gebski VJ, Thompson JF, McCarthy WH,. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997; 19: 589-94.
96. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF,. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012.
97. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF,. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012.
98. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF,. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13: 589-97.
99. Fuhrmann D, Lippold A, Borrosch F, Ellwanger U, Garbe C, Suter L,. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? Br J Dermatol 2001; 144: 66-70.
100. Negrier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dreno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Bosquet L,. [Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations]. Ann Dermatol Venereol 2005; 132: 10S3-10S85.
101. Petrella T, Verma S, Spithoff K, Quirt I, McCready D, Melanoma Disease Site Group. Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma: Updated Guideline Recommendations 2009. Cancer Care Ontario 2009; Evidence-Based Series No.: 8-1, Version 3.2009.
102. Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM, EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402.
103. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B,. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 2005; 55: 38-49.
104. Grossarth-Maticek R, Ziegler R,. Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador). Schweizerische Zeitschrift fur GanzheitsMedizin 2007.
105. Albarranweick M,. Retrospektive Fall-Kontroll-Studie zum Stellenwert der adjuvanten Therapie des malignen Melanoms mit Iscador P.c.Hg. Dissertation, University Freiburg 1998.
106. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM,. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
107. Mocellin S, Pasquali S, Rossi CR, Nitti D,. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
108. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N,. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106: 1431-42.
109. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S,. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-52.
110. Pirard D, Heenen M, Melot C, Vereecken P,. Interferon alpha ≠as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004; 208: 43-8.
111. Lens MB, Dawes M,. Interferon alfa therapy for malignant ≠melanoma: a systematic review of randomized controlled ≠trials. J Clin Oncol 2002; 20: 1818-25.
112. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H, Wolff K,. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425-9.
113. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ,. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351: 1905-10.
114. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U, EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-26.
115. Overgaard J, Overgaard M, Hansen PV, der Maase H,. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986; 5: 183-92.
116. Overgaard J, Overgaard M,. Hyperthermia as an adjuvant to radiotherapy in the treatment of malignant melanoma. Int J Hyperthermia 1987; 3: 483-501.
117. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM,. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hyperthermia 2009; 25: 323-34.
118. Chadha M, Hilaris B, Nori D, Shiu MH, Anderson LL,. Role of brachytherapy in malignant melanoma: a preliminary report. J Surg Oncol 1990; 43: 223-7.
119. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, Urban A, Schell H, Hohenberger W, Sauer R,. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. International journal of radiation oncology, biology, physics 1999; 44: 607-18.
120. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pfohler C, Pawelec G, Garbe C,. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010; 116: 4139-46.
121. Damian DL, Shannon KF, Saw RP, Thompson JF,. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009; 50: 266-71.
122. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, Carretero G,. Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2. Actas Dermosifiliogr. 2009; 100: 571-85.
123. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD,. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol. 2007; 156: 337-45.
124. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ,. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115-21.
125. Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, McCarthy WH,. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15: 45-51.
126. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C,. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89: 1620-6.
127. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J,. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000; 10: 468-74.
128. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z,. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-7.
129. Strobbe LJ, Hart AA, Rumke P, Israels SP, Nieweg OE, Kroon BB,. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997; 7: 507-12.
130. Stas M, Stroobants S, Dupont P, Gysen M, Hoe LV, Garmyn M, Mortelmans L, Wever ID,. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12: 479-90.
131. Dietlein M, Krug B, Groth W, Smolarz K, Scheidhauer K, Psaras T, Stutzer H, Lackner K, Schicha H,. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 1999; 20: 255-61.
132. Kuan AK, Jackson FI, Hanson J,. Multimodality detection of metastatic melanoma. J R Soc Med 1988; 81: 579-82.
133. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S,. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15: 5208-15.
134. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM,. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009; 45: 1807-14.
135. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H,. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 1891-6.
136. Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, Rassner G, Garbe C,. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 1997; 80: 60-5.
137. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH,. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991; 97: 197-202.
138. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM,. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108: 914-9.
139. Prens SP, Van Der Ploeg APT, Van Akkooi ACJ, Van Montfort CAGM, van Geel AN, De Wilt JHW, Eggermont AMM, Verhoef C,. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol 2011; 18: 3586-92.
140. Eggermont AM, Robert C,. New drugs in melanoma: itís a whole new world. Eur J Cancer 2011; 47: 2150-7.
141. Sanki A, Scolyer RA, Thompson JF,. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 2009; 35: 313-9.
142. Leo F, Cagini L, Rocmans P, Cappello M, Geel AN, Maggi G, Goldstraw P, Pastorino U,. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000; 83: 569-72.
143. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, Garbe C,. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79: 2345-53.
144. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
145. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, OíDay SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur AG, Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
146. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
147. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK,. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327-34.
148. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S,. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-9.
149. Robert C, Thomas L, Bondarenko I, OíDay S, M DJW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
150. Hodi FS, OíDay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
151. Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M,. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011; 22: 787-93.
152. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A, on behalf of the EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47: 1476-83.
153. Weber JS, Amin A, Minor D, Siegel J, Berman D, OíDay SJ,. ≠Safety and clinical activity of ipilimumab in melanoma ≠patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011; 21: 530-4.
154. OíDay S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer CJ, Uhlar C, Marshall D, Gore ME, Lang Z, Hait W, Ho P,. A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 2011.
155. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P,. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. MolCancer 2010; 9: 69.
156. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E,. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008; 26: 2178-85.
157. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kampgen E, Schuler G, DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-70.
158. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-45.
159. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y,. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-25.
160. Young AM, Marsden J, Goodman A, Burton A, Dunn JA,. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R.Coll.Radiol) 2001; 13: 458-65.
161. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N,. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66.
162. Falkson CI, Falkson G, Falkson HC,. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-8.
163. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH,. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743-51.
164. Ringborg U, Rudenstam CM, Hansson J, Hafstrom L, Stenstam B, Strander H,. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 1989; 6: 285-9.
165. Thomson DB, Adena M, McLeod GR, Hersey P, Gill PG, Coates AS, Olver IN, Kefford RF, Lowenthal RM, Beadle GF,. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-8.
166. Chauvergne J, Bui NB, Cappelaere P, Gary-Bobo J, Guerrin J, Armand JP, Durand M,. Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone. Sem Hop 1982; 58: 2697-701.
167. Eigentler TK, Caroli UM, Radny P, Garbe C,. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4: 748-59.
168. Chiarion, Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, Favaretto AG, Cetto GL, Monfardini S,. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11: 189-96.
169. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM,. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
170. Luikart SD, Kennealey GT, Kirkwood JM,. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164-8.
171. Carter RD, Krementz ET, Hill GJ, Metter GE, Fletcher WS, Golomb FM, Grage TB, Minton JP, Sparks FC,. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 1976; 60: 601-9.
172. Moon JH, Gailani S, Cooper MR, Hayes DM, Rege VB, Blom J, Falkson G, Maurice P, Brunner K, Glidewell O, Holland JF,. Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 1975; 35: 368-71.
173. Verma S, Petrella T, Hamm C, Bak K, Charette M, and the Melanoma Disease Site Group. Biochemotherapy for the Treatment of Metastatic Malignant Melanoma: A Clinical Practice Guideline. Cancer Care Ontario 2007; Evidence-Based Series No.: 8-3, Section 1, April 2007.
174. Bender CM, Yasko JM, Kirkwood JM, Ryan C, Dunbar-Jacob J, Zullo T,. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res 2000; 9: 352-63.
175. Trask PC, Paterson AG, Esper P, Pau J, Redman B,. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004; 13: 526-36.
176. Rataj D, Jankowiak B, Krajewska-Kulak E, Damme-Ostapowicz K, Nowecki ZI, Rutkowski P, Niczyporuk W,. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs 2005; 28: 172-8.
177. Dixon S, Walters SJ, Turner L, Hancock BW,. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006; 94: 492-8.
178. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A,. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27: 2916-23.
179. Cohen L, Parker PA, Sterner J, De Moor C,. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine. Melanoma Res 2002; 12: 505-11.
180. Cashin RP, Lui P, Machado M, Hemels ME, Corey-Lisle PK, Einarson TR,. Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies. Value Health 2008; 11: 259-71.
181. Kiebert GM, Jonas DL, Middleton MR,. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 2003; 21: 821-9.
182. Sigurdardottir V, Bolund C, Sullivan M,. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996; 35: 149-58.
183. Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, Trefzer U, Drecoll U, Tilgen W, Schadendorf D, Kaatz M, Ulrich J,. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patientís choice: a multicentre Dermatologic Cooperative Oncology Group trial. Melanoma Res 2011; 21: 516-23.
184. Robinson DW, Jr., Cormier JN, Zhao N, Uhlar CM, Revicki DA, Cella D,. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study. Melanoma Res 2011.
185. Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M,. Health-related quality of life before and during adjuvant interferon-alpha treatment for patients with malignant melanoma (DeCOG-trial). J Immunother 2011; 34: 403-8.
186. Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, der Maase H, Hansson J,. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon ≠alfa-2b. Eur J Cancer 2011.
187. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A,. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008; 19: 1195-201.
188. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, JanJan N, Lipsett J,. Fraction size in external beam radiation therapy in the treatment of melanoma. International journal of radiation oncology, biology, physics 1991; 20: 429-32.
189. Herbert SH, Solin LJ, Rate WR, Schultz DJ, Hanks GE,. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma. Cancer 1991; 67: 2472-6.
190. Richtig E, Ludwig R, Kerl H, Smolle J,. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma. Br J Dermatol 2005; 153: 925-31.
191. Engin K, Tupchong L, Waterman FM, Moylan DJ, Nerlinger RE, Leeper DB,. Hyperthermia and radiation in advanced malignant melanoma. International journal of radiation oncology, biology, physics 1993; 25: 87-94.
192. Pyrhonen SO, Kajanti MJ,. The use of large fractions in radiotherapy for malignant melanoma. Radiother Oncol 1992; 24: 195-7.
193. Rounsaville MC, Cantril ST, Fontanesi J, Vaeth JM, Green JP,. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation. Front Radiat Ther Oncol 1988; 22: 62-78.
194. Konefal JB, Emami B, Pilepich MV,. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987; 164: 607-10.
195. Katz HR,. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. International journal of radiation oncology, biology, physics 1981; 7: 907-11.
196. Lobo PA, Liebner EJ, Chao JJ, Kanji AM,. Radiotherapy in the management of malignant melanoma. International journal of radiation oncology, biology, physics 1981; 7: 21-6.
197. Strauss A, Dritschilo A, Nathanson L, Piro AJ,. Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. Cancer 1981; 47: 1262-6.
198. Rate WR, Solin LJ, Turrisi AT,. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. International journal of radiation oncology, biology, physics 1988; 15: 859-64.
199. Doss LL, Memula N,. The radioresponsiveness of melanoma. International journal of radiation oncology, biology, physics 1982; 8: 1131-4.
200. Kirova YM, Chen J, Rabarijaona LI, Piedbois Y, Le Bourgeois JP,. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999; 9: 611-3.
201. Konefal JB, Emami B, Pilepich MV,. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 1988; 61: 243-6.
202. Caralt M, Marti J, Cortes J, Fondevila C, Bilbao I, Fuster J, Garcia-Valdecasas JC, Sapisochin G, Balsells J, Charco R,. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary.Pancreat Sci 2010.
203. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, Peíer J,. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br. J.Ophthalmol. 2009; 93: 1042-6.
204. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, Salmon RJ,. Surgical management of liver metastases from uveal melanoma: 16 yearsí experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-7.
205. Woon WW, Haghighi KS, Zuckerman RS, Morris DL,. Liver resection and cryotherapy for metastatic melanoma. Int Surg 2008; 93: 274-7.
206. Herman P, Machado MA, Montagnini AL, DíAlbuquerque LA, Saad WA, Machado MC,. Selected patients with metastatic melanoma may benefit from liver resection. World J Surg 2007; 31: 171-4.
207. Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Aloia TA, Curley SA, Camacho LH, Capussotti L, Elias D, Vauthey JN,. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006; 13: 712-20.
208. Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, Thompson JF, Morton DL,. Surgical resection for metastatic ≠melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001; 136: 950-5.
209. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, Pouillart P, Schlienger P, Servois V, Asselain B,. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 1998; 24: 127-30.
210. Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY,. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest 2011; 29: 49-55.
211. Huppert PE, Fierlbeck G, Pereira P, Schanz S, Duda SH, Wietholtz H, Rozeik C, Claussen CD,. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010; 74: e38-e44.
212. Schuster R, Lindner M, Wacker F, Krossin M, Bechrakis N, Foerster MH, Thiel E, Keilholz U, Schmittel A,. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010; 20: 191-6.
213. Fiorentini G, Aliberti C, Del Conte A, Tilli M, Rossi S, Ballardini P, Turrisi G, Benea G,. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009; 23: 131-7.
214. Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, Beny A, Dezarn WA,. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27: 682-90.
215. Melichar B, Voboril Z, Lojik M, Krajina A,. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepatogastroenterology 2009; 56: 1157-62.
216. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T,. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009; 252: 290-8.
217. Rizell M, Mattson J, Cahlin C, Hafstrom L, Lindner P, Olausson M,. Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res 2008; 18: 120-6.
218. Sharma KV, Gould JE, Harbour JW, Linette GP, Pilgram TK, Dayani PN, Brown DB,. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol 2008; 190: 99-104.
219. Siegel R, Hauschild A, Kettelhack C, Kahler KC, Bembenek A, Schlag PM,. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007; 33: 627-32.
220. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S,. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17: 578-83.
221. Vogl T, Eichler K, Zangos S, Herzog C, Hammerstingl R, Balzer J, Gholami A,. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007; 133: 177-84.
222. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T,. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005; 15: 297-304.
223. Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T,. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9: 6343-9.
224. Alexander HR, Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T,. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9: 6343-9.
225. Khayat D, Cour V, Bizzari JP, Aigner K, Borel C, Cohen-Alloro G, Weil M, Auclerc G, Buthiau D, Bousquet JC,. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. Am J Clin Oncol 1991; 14: 400-4.
226. Storm FK, Kaiser LR, Goodnight JE, Harrison WH, Elliott RS, Gomes AS, Morton DL,. Thermochemotherapy for melanoma metastases in liver. Cancer 1982; 49: 1243-8.
227. Agarwala SS, Panikkar R, Kirkwood JM,. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004; 14: 217-22.
228. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Brocker EB,. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87: 840-5.
229. Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, de Gislain C, Bensadoun RJ, Clavel M,. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003; 13: 97-103.
230. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C, Schadendorf D, on behalf of the Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2010.
231. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH, Gutin PH,. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10: 199-207.
232. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF,. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22: 1293-300.
233. Wronski M, Arbit E,. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 2000; 93: 9-18.
234. Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, OíDwyer PJ, Flaherty KT,. Phase II Trial of ≠Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res 2009; 15: 7711-8.
235. Vestermark LW, Larsen S, Lindelov B, Bastholt L,. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol 2008; 47: 1526-30.
236. Larkin JM, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, Thomas K, Eisen TG, Gore ME,. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007; 96: 44-8.
237. Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T, Tilgen W, Mohr P, Garbe C,. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 2006; 17: 1592-7.
238. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN,. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005; 103: 2590-7.
239. Bafaloukos D, Tsoutsos D, Fountzilas G, Linardou H, Christodoulou C, Kalofonos HP, Briassoulis E, Panagiotou P, Hatzichristou H, Gogas H,. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 2004; 14: 289-94.
240. Chang J, Atkinson H, AíHern R, Lorentzos A, Gore ME,. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from ≠malignant melanoma. Eur J Cancer 1994; 30A: 2093-5.
241. Jacquillat C, Khayat D, Banzet P, Weil M, Avril MF, Fumoleau P, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ,. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25: 263-6.
242. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM,. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22: 2101-7.
243. Leiter U, Buettner PG, Eigentler TK, Br̂cker EB, Voit C, Gollnick H, Marsch W, Wollina U, Meier F, Garbe C,. Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol 2011.
244. Hohnheiser AM, Gefeller O, Gohl J, Schuler G, Hohenberger W, Merkel S,. Malignant melanoma of the skin: long-term follow-up and time to first recurrence. world j. surg. 2010.
245. Rueth NM, Groth SS, Tuttle TM, Virnig BA, Al Refaie WB, Habermann EB,. Conditional survival after surgical treatment of melanoma: an analysis of the Surveillance, Epidemiology, and End Results database. Ann Surg Oncol 2010; 17: 1662-8.
246. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC,. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999; 86: 2252-8.
247. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, Hunter JA,. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140: 249-54.
248. Hengge UR, Wallerand A, Stutzki A, Kockel N,. Cost-effectiveness of reduced follow-up in malignant melanoma. J Dtsch Dermatol Ges 2007; 5: 898-907.
249. Leiter U, Marghoob AA, Lasithiotakis K, Eigentler TK, Meier F, Meisner C, Garbe C,. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Res 2009; 19: 50-7.
250. Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, Collet-Vilette AM, Lota I, Bonerandi JJ,. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995; 191: 199-203.
251. Voit C, Mayer T, Kron M, Schoengen A, Sterry W, Weber L, Proebstle TM,. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer 2001; 91: 2409-16.
252. Aukema TS, Olmos RA, Korse CM, Kroon BB, Wouters MW, Vogel WV, Bonfrer JM, Nieweg OE,. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol 2010; 17: 1657-61.
253. Brown RE, Stromberg AJ, Hagendoorn LJ, Hulsewede DY, Ross MI, Noyes RD, Goydos JS, Urist MM, Edwards MJ, Scoggins CR, McMasters KM, Martin RC,. Surveillance after surgical treatment of melanoma: futility of routine chest radiography. Surgery 2010; 148: 711-6.
254. Morton RL, Craig JC, Thompson JF,. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann. Surg.Oncol. 2009; 16: 571-7.
255. Rinne D, Baum RP, Hor G, Kaufmann R,. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664-71.
256. Kaufmann PM, Crone-Munzebrock W,. Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma]. Aktuelle Radiol 1992; 2: 81-5.
257. Hausmann D, Jochum S, Utikal J, Hoffmann RC, Zechmann C, Neff KW, Goerdt S, Schoenberg SO, Dinter DJ,. Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanoma. JDDG-Journal of the German Society of Dermatology 2011; 9: 212-22.
258. DeRose ER, Pleet A, Wang W, Seery VJ, Lee MY, Renzi S, Sullivan RJ, Atkins MB,. Utility of 3-year torso computed ≠tomography and head imaging in asymptomatic patients ≠with high-risk melanoma. Melanoma Res 2011; 21: 364-9.
259. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB,. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010; 28: 3042-7.
260. Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC,. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007; 244: 566-74.
261. Mehnert A, Petersen C, Koch U,. Empfehlungen zur Psychoonkologischen Versorgung im Akutkrankenhaus. Zeitschrift fr Medizinische Psychologie 2003; 12: 77-84.
262. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ,. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.